Answers are grounded in this paper and cite their sources.
Key Points Selective myeloma cell killing and enhanced effector function of a novel anti-BCMA antibody conjugated with MMAF via noncleavable linker. Specific multiple myeloma antigen for monoclonal antibody-based immunotherapy.
No takes yet. Share an insight, caveat, or question.
Tai et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: